EMA Refused: Masiviera (masitinib) — AB Science

View source ↗

Summary

The EMA refused approval for Masiviera (masitinib) for pancreatic neoplasms, with AB Science as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• Masiviera (masitinib)

Snippet

Status: Refused. Therapeutic area: Pancreatic Neoplasms. MAH: AB Science. Decision date: 23/01/2014. Orphan medicine